Orchid Pharma Limited
NSE: ORCHPHARMA
NSE
718.15
-4.85 (-0.67%)
Prev Close
723
Open Price
724.5
Volume
149,821
Today Low / High
709.3 / 733.45
52 WK Low / High
603.8 / 1997.4
Range
682 - 754
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 718.15, with a change of -4.85 (-0.67082%). The expected target range on the NSE is between 682 - 754. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
06 Jun
724.50
-0.88%
05 Jun
737.00
-1.90%
04 Jun
690.90
4.78%
03 Jun
693.15
-0.45%
02 Jun
650.00
1.56%
30 May
603.80
4.13%
29 May
655.00
-2.97%
28 May
704.20
-5.00%
27 May
704.20
0.00%
26 May
764.00
-2.98%
23 May
729.90
3.64%
22 May
730.30
-1.05%
21 May
730.00
1.09%
20 May
770.00
-5.38%
19 May
775.00
-2.06%
16 May
793.00
-3.27%
15 May
785.00
-0.53%
14 May
795.00
-1.18%
13 May
787.85
0.88%
12 May
776.00
1.21%
09 May
775.00
0.12%
Orchid Pharma Limited Graph
Orchid Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Orchid Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 718.15, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 718.15 | 725.33 | 652.80 - 797.86 |
| 732.51 | 586.01 - 879.02 | ||
| 739.69 | 517.79 - 961.60 | ||
| Bearish Scenario | 718.15 | 710.97 | 639.87 - 782.07 |
| 703.79 | 563.03 - 844.54 | ||
| 696.61 | 487.62 - 905.59 |
Overview of Orchid Pharma Limited
ISIN
INE191A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
144,416
Market Cap
36,423,921,665
Last Dividend
0
Official Website
IPO Date
2002-07-01
DCF Diff
534.63
DCF
184
Financial Ratios Every Investor Needs
Stock Dividend of ORCHPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2012-09-13 | September 13, 12 | 3 | 0.0138 | |||
| 2011-07-19 | July 19, 11 | 3 | 0.0138 | |||
| 2010-07-12 | July 12, 10 | 10 | 0.0459 | |||
| 2009-09-17 | September 17, 09 | 1 | 0.0046 | |||
| 2008-09-18 | September 18, 08 | 3 | 0.0138 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 819.07 Cr | 503.18 Cr | 315.88 Cr | 0.3857 | 7.09 Cr | 8.43 Cr | 78.47 Cr | 92.17 Cr | 19.06 | 141.92 Cr | 0.1125 |
| 2023-03-31 | 665.90 Cr | 401.25 Cr | 264.64 Cr | 0.3974 | 6.36 Cr | 8.79 Cr | 29.67 Cr | 46.32 Cr | 11.35 | 142.94 Cr | 0.0696 |
| 2022-03-31 | 559.56 Cr | 327.09 Cr | 232.47 Cr | 0.4154 | 6.63 Cr | 8.90 Cr | -33.89 Cr | -1.95 Cr | -0.48 | 63.58 Cr | -0.0035 |
| 2021-03-31 | 450.06 Cr | 241.30 Cr | 208.76 Cr | 0.4638 | 4.81 Cr | 12.90 Cr | -50.49 Cr | -116.53 Cr | -28.55 | 65.87 Cr | -0.2589 |
| 2020-03-31 | 483.80 Cr | 224.02 Cr | 259.78 Cr | 0.5370 | 11.93 Cr | 23.99 Cr | -70.10 Cr | -131.07 Cr | -14.75 | 52.39 Cr | -0.2709 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3.60 Cr | 1,553.87 Cr | 384.41 Cr | 1,169.4661 Cr | 135.18 Cr | 131.58 Cr | 264.23 Cr | 645.12 Cr | 0.00 Cr | 0.00 Cr | 45.84 Cr | 259.9743 Cr |
| 2023-03-31 | 22.60 Cr | 1,225.21 Cr | 536.56 Cr | 688.6490 Cr | 331.35 Cr | 308.75 Cr | 228.74 Cr | 619.17 Cr | 1.68 Cr | 0.00 Cr | 44.44 Cr | 371.8917 Cr |
| 2022-03-31 | 4.31 Cr | 1,110.56 Cr | 463.18 Cr | 647.3799 Cr | 267.95 Cr | 263.65 Cr | 172.66 Cr | 604.82 Cr | 0.00 Cr | 0.00 Cr | 45.50 Cr | 240.7783 Cr |
| 2021-03-31 | 15.69 Cr | 1,237.25 Cr | 584.34 Cr | 652.9078 Cr | 452.74 Cr | 437.05 Cr | 152.89 Cr | 677.51 Cr | 0.04 Cr | 0.00 Cr | 0.42 Cr | 142.0818 Cr |
| 2020-03-31 | 89.89 Cr | 1,459.91 Cr | 693.92 Cr | 765.9848 Cr | 566.39 Cr | 476.50 Cr | 141.69 Cr | 858.77 Cr | 0.00 Cr | 0.00 Cr | 0.34 Cr | 174.9382 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 125.9920 Cr | -312.0286 Cr | 167.0404 Cr | 61.1772 Cr | -18.9962 Cr | 3.6009 Cr | -64.8148 Cr | 92.1665 Cr | -208.5472 Cr | 0.0000 Cr | -35.4881 Cr |
| 2023-03-31 | 18.3380 Cr | -31.2139 Cr | 31.1664 Cr | -66.5751 Cr | 18.2905 Cr | 22.5971 Cr | -84.9131 Cr | 46.3183 Cr | 63.3921 Cr | 0.0000 Cr | -56.0817 Cr |
| 2022-03-31 | 92.4746 Cr | 112.9362 Cr | -216.7981 Cr | 78.0711 Cr | -11.3873 Cr | 4.3066 Cr | -14.4035 Cr | -1.9512 Cr | -184.7864 Cr | 0.0000 Cr | 2.5369 Cr |
| 2021-03-31 | 23.5860 Cr | 67.2051 Cr | -164.9887 Cr | 22.9820 Cr | -74.1976 Cr | 15.6939 Cr | -0.6040 Cr | -116.5300 Cr | -125.0800 Cr | 0.0000 Cr | -33.4985 Cr |
| 2020-03-31 | 80.8030 Cr | 167.1121 Cr | -250.3345 Cr | 76.5606 Cr | -2.4194 Cr | 89.8915 Cr | -4.2424 Cr | -131.0701 Cr | -290.0092 Cr | 0.0000 Cr | 14.0628 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 217.34 Cr | 124.79 Cr | 92.55 Cr | 0.4258 | 61.89 Cr | 20.78 Cr | 4.10 | 34.85 Cr | 0.0956 |
| 2024-09-30 | 222.70 Cr | 131.16 Cr | 91.54 Cr | 0.4110 | 21.71 Cr | 27.24 Cr | 5.37 | 37.85 Cr | 0.1223 |
| 2024-06-30 | 244.41 Cr | 150.25 Cr | 94.15 Cr | 0.3852 | 24.05 Cr | 29.35 Cr | 5.79 | 40.06 Cr | 0.1201 |
| 2024-03-31 | 217.10 Cr | 146.85 Cr | 70.26 Cr | 0.3236 | 20.50 Cr | 33.53 Cr | 6.81 | 42.28 Cr | 0.1544 |
| 2023-12-31 | 220.59 Cr | 121.94 Cr | 98.65 Cr | 0.4472 | 70.24 Cr | 29.43 Cr | 6.18 | 43.01 Cr | 0.1334 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 4.35 Cr | 243.59 Cr | 247.94 Cr | 215.20 Cr | 320.58 Cr | 833.37 Cr | 656.15 Cr | 1,635.14 Cr | 410.90 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 3.62 Cr | 0.00 Cr | 0.00 Cr | 3.62 Cr | 0.00 Cr | 0.00 Cr | -1,169.47 Cr |
| 2024-03-31 | 3.60 Cr | 0.01 Cr | 4.52 Cr | 200.35 Cr | 264.23 Cr | 790.75 Cr | 645.12 Cr | 1,553.87 Cr | 384.41 Cr |
| 2023-12-31 | -50.36 Cr | 100.73 Cr | 50.36 Cr | 0.00 Cr | 0.00 Cr | 50.36 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 40.42 Cr | 14.93 Cr | 55.35 Cr | 187.59 Cr | 222.36 Cr | 497.40 Cr | 622.48 Cr | 1,492.08 Cr | 384.24 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 29.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 33.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 29.43 Cr | 18.54 Cr | 0.00 Cr | 0.00 Cr | 18.54 Cr | 68.90 Cr | 50.36 Cr | 0.00 Cr | 18.54 Cr |
| 2023-09-30 | 19.80 Cr | 15.68 Cr | 0.00 Cr | 0.00 Cr | 15.68 Cr | 50.36 Cr | 34.68 Cr | 0.00 Cr | 15.68 Cr |
| 2023-06-30 | 9.40 Cr | 15.42 Cr | 0.00 Cr | 0.00 Cr | 15.42 Cr | 42.03 Cr | 26.61 Cr | 0.00 Cr | 15.42 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-07-25 | July 25, 19 | 1:218 |
| 2005-09-15 | September 15, 05 | 3:2 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Head of Medico Marke
Mr. Prabhu Vinayagam
Gender: male
Year Born: 1970
Whole Time Director
Mr. Mridul Dhanuka
Gender: male
Year Born: 1980
Vice President and Unit Head of API & FDF
Dr. R. J. Sarangdhar
Gender: Not Specified
Year Born: 1964
Company Secretary & Compliance Officer
Mr. Kapil Dayya
Gender: male
Year Born:
President of API, CSR and SH & E
Mr. Sivaswami Mani
Gender: male
Year Born: 1960
Chief Executive Officer of Orchid AMS
Mr. Rajnish Rohatgi B. Tech.
Gender: male
Year Born: 1962
Head of Human Resources
Mr. Ashok Clifford D
Gender: male
Year Born: 1973
Chief Financial Officer
Mr. Sunil Kumar Gupta
Gender: male
Year Born: 1963
Head of CTD & IPM
Dr. S. Srinivasan
Gender: Not Specified
Year Born: 1971
MD & Director
Mr. Manish Dhanuka
Gender: male
Year Born: 1967
FAQs about Orchid Pharma Limited
Who is the CEO of the company?
The CEO is Mr. Rajnish Rohatgi B. Tech..
What is the current market price of the stock?
The current price is ₹718.15.
What is the 52-week price range?
The range is ₹603.8-1997.4.
What is the market capitalization of the company?
The market capitalization is ₹3,642.39 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 32.82.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Orchid Pharma Limited (ISIN: INE191A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,642.39 crores and an average daily volume of 144,416 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.